Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty
The purpose of my doctoral thesis was to compare acute and late toxicity after three-dimensional conformal radiotherapy to the prostate to 74 Gy with intensity-modulated radioterapy (IMRT) to 78 Gy and IMRT using simultaneus integrated boost to 82 Gy. Ninety-four patients treated with conformal radi...
Main Author: | |
---|---|
Other Authors: | |
Format: | Doctoral Thesis |
Language: | Czech |
Published: |
2010
|
Online Access: | http://www.nusl.cz/ntk/nusl-299729 |
id |
ndltd-nusl.cz-oai-invenio.nusl.cz-299729 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-nusl.cz-oai-invenio.nusl.cz-2997292021-02-26T05:19:41Z Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty Simultaneous integrated boost in the treatment of localized prostate cancer Doležel, Martin Odrážka, Karel Šlampa, Pavel Kovařík, Josef The purpose of my doctoral thesis was to compare acute and late toxicity after three-dimensional conformal radiotherapy to the prostate to 74 Gy with intensity-modulated radioterapy (IMRT) to 78 Gy and IMRT using simultaneus integrated boost to 82 Gy. Ninety-four patients treated with conformal radiotherapy to the prostate and base of seminal vesicles to 74 Gy represented the first group. The second group consisted of 138 patients irradiated with IMRT covering the prostate and base of seminal vesicles to 78 Gy. The last group was treated with IMRT using simultaneus integrated boost. The prescribed doses were 82 Gy and 73. 8 Gy in 42 fractions to prostate and to seminal vesicles. Late toxicity was prospectively scored according to the RTOG/FC-LENT scale. Acute gastrointestinal toxicity Grade 2 or greater occured in 35.1% patients treated with 3D-CRT, 16% with IMRT 78 and 7.7% using IMRT/SIB 82. Acute urogenital toxicity Grade 2 or greater was presented in 26.6% (3D-CRT), 33% (IMRT 78) and 30.7% (IMRT/SIB 82). At 3 years, the estimated cumulative incidence of Grade 3 late gastrointestinal toxicity was 14% for 3D-CRT, 5% for IMRT 78 and 2% for IMRT/SIB 82. The difference became significant (log rank p=0.02). The estimated cumulative incidence of Grade 3 late urogenital toxicity was 9% (3D-CRT), 7%... 2010 info:eu-repo/semantics/doctoralThesis http://www.nusl.cz/ntk/nusl-299729 cze info:eu-repo/semantics/restrictedAccess |
collection |
NDLTD |
language |
Czech |
format |
Doctoral Thesis |
sources |
NDLTD |
description |
The purpose of my doctoral thesis was to compare acute and late toxicity after three-dimensional conformal radiotherapy to the prostate to 74 Gy with intensity-modulated radioterapy (IMRT) to 78 Gy and IMRT using simultaneus integrated boost to 82 Gy. Ninety-four patients treated with conformal radiotherapy to the prostate and base of seminal vesicles to 74 Gy represented the first group. The second group consisted of 138 patients irradiated with IMRT covering the prostate and base of seminal vesicles to 78 Gy. The last group was treated with IMRT using simultaneus integrated boost. The prescribed doses were 82 Gy and 73. 8 Gy in 42 fractions to prostate and to seminal vesicles. Late toxicity was prospectively scored according to the RTOG/FC-LENT scale. Acute gastrointestinal toxicity Grade 2 or greater occured in 35.1% patients treated with 3D-CRT, 16% with IMRT 78 and 7.7% using IMRT/SIB 82. Acute urogenital toxicity Grade 2 or greater was presented in 26.6% (3D-CRT), 33% (IMRT 78) and 30.7% (IMRT/SIB 82). At 3 years, the estimated cumulative incidence of Grade 3 late gastrointestinal toxicity was 14% for 3D-CRT, 5% for IMRT 78 and 2% for IMRT/SIB 82. The difference became significant (log rank p=0.02). The estimated cumulative incidence of Grade 3 late urogenital toxicity was 9% (3D-CRT), 7%... |
author2 |
Odrážka, Karel |
author_facet |
Odrážka, Karel Doležel, Martin |
author |
Doležel, Martin |
spellingShingle |
Doležel, Martin Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty |
author_sort |
Doležel, Martin |
title |
Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty |
title_short |
Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty |
title_full |
Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty |
title_fullStr |
Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty |
title_full_unstemmed |
Využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty |
title_sort |
využití simultánního integrovaného boostu v léčbě lokalizovaného karcinomu prostaty |
publishDate |
2010 |
url |
http://www.nusl.cz/ntk/nusl-299729 |
work_keys_str_mv |
AT dolezelmartin vyuzitisimultannihointegrovanehoboostuvlecbelokalizovanehokarcinomuprostaty AT dolezelmartin simultaneousintegratedboostinthetreatmentoflocalizedprostatecancer |
_version_ |
1719379576205869056 |